Abstract 254TiP
Background
Cabozantinib plus nivolumab (Cabo/Nivo) for patients with previously untreated advanced or metastatic clear cell renal cell carcinoma (ccRCC) demonstrated significant improvement of clinical outcomes, compared with sunitinib, in a randomized phase III trial (CheckMate-9ER). The results support Cabo/Nivo as standard regimen in global guidelines for those patients. However, limited numbers of Japanese patients were enrolled in the trial, and little information on the safety and efficacy in Japanese patients is available. Several previous studies, especially on vascular endothelial growth factor receptor (VEGFR) inhibitor-induced toxicity, have reported ethnic differences; therefore, it is important to clarify toxicity profiles in Japanese patients. Furthermore, there is limited information on this regimen for special populations in the real-world, such as patients with non-clear cell renal cell carcinoma (nccRCC) or those undergoing dialysis. This study evaluates the real-world efficacy and toxicity of Cabo/Nivo in Japanese patients with both ccRCC and nccRCC.
Trial design
We conducted a prospective observational study to evaluate Cabo/Nivo treatment in Japanese patients with advanced or metastatic RCC in the realworld. A total of 72 institutions throughout Japan have been participating in this study from April 2023. This study consists of two cohorts: cohort A (ccRCC) and cohort B (nccRCC). The target enrollment is 150 in cohort A and 50 in cohort B. Key inclusion criteria includes (1) histologically diagnosed with ccRCC or nccRCC, (2) clinically diagnosed with advanced or metastatic RCC, (3) patients received Cabo/Nivo, (4) previously untreated with systemic therapy (patients who recur more than 180 days after the last administration of adjuvant PD-1 or PD-L1 inhibitor therapy are allowed), (5) KPS score of ≥70%. Primary endpoint is overall response rate in each cohort, Secondary endpoints are progression-free survival, duration of response, overall survival, and safety in each cohort. Forty-three and 13 patients have been enrolled in cohorts A and B, respectively, as of July 2023.
Clinical trial identification
UMIN000050778.
Legal entity responsible for the study
Clinical Research Support Center Kyushu.
Funding
Takeda Pharmaceutical Company Limited.
Disclosure
Y. Miura: Financial Interests, Personal, Invited Speaker: Takeda, MSD, Bristol Myers Squibb, Ono Pharmaceutical, Merck BioPharma, Eisai, Astellas Pharma; Financial Interests, Institutional, Local PI: Ono Pharmaceutical, MSD. K. Fujita: Financial Interests, Personal, Other, Honoraria: Ono Pharmaceutical, Bristol Myers Squibb, Astellas, AstraZeneca. S. Tamada: Financial Interests, Personal, Speaker’s Bureau: Takeda, Pfizer, Merck-Biopharma, MSD. C. Ohe: Financial Interests, Personal, Other, Honoraria: Takeda, MSD KK, Ono Pharmaceutical. M. Eto: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Eisai, MSD, Ono Pharmaceutical, Takeda Pharmaceutical, Bristol Myers Squibb, Merck, Astellas Pharma, Pfizer, Janssen Pharmaceutical; Financial Interests, Personal, Advisory Role: Eisai, Pfizer, Takeda Pharmaceutical, Merck, Chugai Pharmaceutical; Financial Interests, Personal, Research Grant: Takeda Pharmaceutical. M. Oya: Financial Interests, Personal, Other, Honoraria: Astellas, Janssen, AstraZeneca, Takeda, Bayer, MSD; Financial Interests, Personal, Research Grant: Astellas. T. Kamba: Financial Interests, Personal, Other, Honoraria: Takeda Pharmaceutical, AstraZeneca, Merck Biopharma. N. Shinohara: Financial Interests, Personal, Other, Honoraria: MSD, Takeda, BMS, Ono, Eisai, Pfizer; Financial Interests, Personal, Advisory Role: Takeda; Financial Interests, Personal, Research Grant: Ono, Takeda. T. Tsuzuki: Financial Interests, Personal, Other, Honoraria: MSD, Ono, Bristol Myers Squibb, Janssen, AstraZeneca, Nippon Kayaku, Takeda, Astellas, Bayer, Pfizer, Merck; Financial Interests, Personal, Advisory Role: Janssen, SBI, Ferring; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb. N. Nonomura: Financial Interests, Personal, Other, Honoraria: Takeda, Janssen, Merck Biopharma, Ono, Bristol; Financial Interests, Personal, Officer, Honoraria: AstraZeneca. Y. Fujii: Financial Interests, Personal, Advisory Role: Takeda Pharmaceuticals; Financial Interests, Personal, Speaker’s Bureau: Ono Pharmaceutical, Takeda Pharmaceuticals. G. Kimura: Financial Interests, Personal, Other, Honoraria: Ono, BMS, Bayer, Merck Biopharma, MSD, Eisai, Takeda, Astellas, Janssen. H. Uemura: Financial Interests, Institutional, Research Grant: Astellas, Takeda, MSD, Janssen, Pfizer; Financial Interests, Institutional, Research Funding: AstraZeneca, Ono Pharmaceutical, Osaka Urology Research foundation; Financial Interests, Personal, Speaker, Consultant, Advisor: Takeda, Janssen, Pfizer, BMS, Sanofi, Bayer; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Role: Ono Pharmaceutical; Financial Interests, Personal, Project Lead: Chugai. All other authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract